MGMT and central nervous system cancer: According to the report of the National Comprehensive Cancer Network, many potential glioma biomarkers have been identified and utilized, including mutated isocitrate dehydrogenase (IDH) and O-6-methylguanine-DNA methyltransferase (MGMT) genes, 1p/19q co-deletion status, BRAF fusion, and CpG island methylator phenotype [6, 7].